CARIO Centre Armoricain de Radiotherapie D'Imagerie medicale et D'Oncologie

Plerin 29 trials 11 recruiting

29 Registered trials

11 Currently recruiting

Organisation

CARIO Centre Armoricain de Radiotherapie D'Imagerie medicale et D'Oncologie

Location

Plerin, France

Identifier

ORG-100051182

Address

10 Rue Francois Jacob, 22190, France

Departments

Medical Oncology
Oncologie
Oncologie médicale
ONCOLOGIE OPTION MEDICALE
Oncologue
Oncology
Radiotherapy Oncology
Service d'Oncologie Médicale
Service Oncologie Médicale

Clinical trials at this site (29)

Search interface

Study of the effect and tolerability of INT230-6 by direct injection into the tumor, followed by neoadjuvant treatment with chemoimmunothera… Pending

2024-512511-49-00 Early triple-negative breast cancer (TNBC) 4
TAILORswitch (PADA-2): rising ctDNA to tailor endocrine therapy switch in patients with ER+/HER2- metastatic breast cancer. Pending

2025-524213-84-00 Patients with advanced or metastatic ER+ HER2- breast c 5
A Global Phase III Study of Puxitatug Samrotecan (AZD8205) Monotherapy Compared with Physician’s Choice of Chemotherapy for B7-H4-Selected E… Recruiting

2024-518777-34-00 B7-H4-Selected Advanced/Metastatic Endometrial Cancer. 5 2026-02-11
NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting

2025-520979-13-00 Patients with HR+ HER2- early breast cancer at intermed 5 2025-12-18
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer (TREVI-OC-01) Recruiting

2025-520466-22-00 Advanced Platinum-resistant Epithelial Ovarian Cancer 5 2026-04-29
A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg… Recruiting

2025-523083-21-00 PIK3CA-mutant Hormone Receptor Positive, Human Epiderma 5 2025-12-08
A study to evaluate dosing schedules of mirvetuximab soravtansine in patients with epithelial ovarian, primary peritoneal, or fallopian tube… Recruiting

2024-517184-23-00 platinum-resistant advanced high-grade epithelial ovari 4 2025-10-16
ENGIC 01 - COLOSOTO: A single-arm phase II study evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib (KRAS G12C inhibitor) … Recruiting

2024-514030-20-00 colorectal cancer 4 2025-08-29
A Study to Assess safety and Effectiveness of the Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor an… Recruiting

2024-516162-11-00 Endocrine-Sensitive phosphatidylinositol 3-kinase (PIK3 5 2025-07-14
Decreasing treatment for metastatic HER2-Positive Breast Cancer with undetectable cancer levels in blood tests Recruiting

2023-509811-98-00 Patients with HER2-positive locally advanced inoperable 4 2025-01-07
An international multicentric randomized phase II evaluating dostarlimab in combination with niraparib versus niraparib alone compared to ch… Recruiting

2024-516782-36-00 metastatic or recurrent endometrial or ovarian carcinos 4 2024-10-15
PRODIGE 70 - CIRCULATE - CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II Recruiting

2024-515297-27-00 colon carcinoma 5 2024-08-14
Treatment of microstellite stable metastatic colorectal cancer presenting high immune infiltrate with chemotherapy (XELOX or FOLFOX Bevacizu… Recruiting

2024-515788-73-00 MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCE 4 2024-07-30
Phase 2 Pan-Tumor Trial of R-DXd for Advanced/Metastatic Solid Tumors Ended

2024-513307-13-00 Advanced/metastatic solid tumors including gynecologica 4 2025-05-26
A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL C… Ended

2024-514032-25-00 Patients with a histilogically confirmed diagnosis of c 4 2024-12-11
Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-… Ended

2024-513540-29-00 Breast Cancer 5 2024-11-07
A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment with Mirvetuximab Soravtansine in Patients with Rec… Ended

2023-505617-24-00 Recurrent Ovarian Cancer with High Folate Receptor-Alph 4 2024-11-05
MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer Ended

2023-504816-14-00 Endometrial cancer 5 2024-03-08
A phase 3 clinical trial of a new combination treatment, domvanalimab and zimberelimab, plus chemotherapy, for people with an upper gastroin… Ended

2023-507522-16-00 Metastatic Esophageal or Gastric Cancer 5 2023-05-22
Durvalumab (immunotherapy) maintenance after thoracic chemoradiotherapy (CRT) in frail small cell lung cancer patients whose disease is limi… Ended

2024-512224-11-00 Histologically confirmed frail Limited Disease Small Ce 4 2023-03-24
Multicentric randomized phase I / II study to evaluate efficacy of trifluridine/tipiracil +/- bevacizumab plus XB2001 (anti-IL-1α True Human… Ended

2024-517024-20-00 Metastatic colorectal cancer patients 9 2022-09-27
Evaluation of two maintenance therapies (OSE2101 alone or in combination with pembrolizumab) versus best supportive care in patient with pla… Ended

2024-516096-32-00 Platinum sensitive recurrent ovarian cancer 4 2021-08-05
Study comparing two standard treatments as initial metastatic treatment among patients with visceral metastasis of ER+ HER2- breast cancer, … Ended

2024-513005-31-00 Patients with untreated metastatic Estrogen Receptor po 5 2020-06-11
Study assessing the efficacy and safety of durvalumab plus olaparib plus fulvestrant in selected metastatic or locally advanced ER-positive,… Ended

2024-516847-23-00 ER-positive and HER2-negative metastatic or locally adv 4 2019-08-27